Two tiered biological containment strategy for Lactococcus lactis-based vaccine or immunotherapy vectors

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 2, 2014, Pages 333-337

  Hanin, Aurelie ^a,b   Culligan, Eamonn P ^a,b   Casey, Pat G ^a,b   Bahey El Din, Mohammed ^c   Hill, Colin ^a,b   Gahan, Cormac G M ^a,b  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

^c Alexandria University Faculty of Pharmacy   (Egypt)

Author keywords

Biological containment; Lactococcus lactis; PyrG; ThyA; Vaccine

Indexed keywords

BACTERIAL VECTOR; CYTIDINE TRIPHOSPHATE SYNTHASE; DRUG CARRIER; LIGASE; THYMIDYLATE SYNTHASE; VACCINE;

ARTICLE; BACTERIAL GENE; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIAL SURVIVAL; BACTERIAL VIABILITY; BIOENGINEERING; BIOSAFETY; DNA SEQUENCE; DOWN REGULATION; DRUG DELIVERY SYSTEM; GENE DELETION; LACTOCOCCUS LACTIS; NONHUMAN; PHENOTYPE; PLASMID; PROMOTER REGION; THYA GENE; ANIMAL; DEFICIENCY; ENZYMOLOGY; GASTROINTESTINAL TRACT; GENETICS; GROWTH, DEVELOPMENT AND AGING; HAZARDOUS WASTE; IMMUNOLOGY; IMMUNOTHERAPY; MICROBIOLOGY; MOUSE; PROCEDURES;

ANIMALS; CARBON-NITROGEN LIGASES; CONTAINMENT OF BIOHAZARDS; DRUG CARRIERS; GASTROINTESTINAL TRACT; IMMUNOTHERAPY; LACTOCOCCUS LACTIS; MICE; THYMIDYLATE SYNTHASE; VACCINES;

EID: 84896943488     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.26954     Document Type: Article

References (25)

1. Bahey-El-Din M, Casey PG, Griffin BT, Gahan CGM. Lactococcus lactis-expressing listeriolysin O (LLO) provides protection and specific CD8(+) T cells against Listeria monocytogenes in the murine infection model. Vaccine 2008; 26:5304-14; PMID:18691625; http://dx.doi.org/10.1016/j.vaccine.2008.07.047
2. Bahey-El-Din M, Casey PG, Griffin BT, Gahan CG. Efficacy of a Lactococcus lactis ?pyrG vaccine delivery platform expressing chromosomally integrated hly from Listeria monocytogenes. Bioeng Bugs 2010; 1:66- 74; PMID:21327128; http://dx.doi.org/10.4161/ bbug.1.1.10284
3. Bahey-El-Din M, Casey PG, Griffin BT, Gahan CGM. Expression of two Listeria monocytogenes antigens (P60 and LLO) in Lactococcus lactis and examination for use as live vaccine vectors. J Med Microbiol 2010; 59:904-12; PMID:20488938; http://dx.doi. org/10.1099/jmm.0.018770-0
4. Bahey-El-Din M, Gahan CGM. Lactococcus lactisbased vaccines: current status and future perspectives. Hum Vaccin 2011; 7:106-9; PMID:21263226; http://dx.doi.org/10.4161/hv.7.1.13631
5. Bahey-El-Din M. Lactococcus lactis-based vaccines from laboratory bench to human use: an overview. Vaccine 2012; 30:685-90; PMID:22154771; http://dx.doi.org/10.1016/j.vaccine.2011.11.098
6. Caluwaerts S, Vandenbroucke K, Steidler L, Neirynck S, Vanhoenacker P, Corveleyn S, Watkins B, Sonis S, Coulie B, Rottiers P. AG013, a mouth rinse formulation of Lactococcus lactis secreting human Trefoil Factor 1, provides a safe and efficacious therapeutic tool for treating oral mucositis. Oral Oncol 2010; 46:564-70; PMID:20542722; http://dx.doi. org/10.1016/j.oraloncology.2010. 04.008
7. Wells JM, Mercenier A. Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat Rev Microbiol 2008; 6:349- 62; PMID:18345021; http://dx.doi.org/10.1038/ nrmicro1840 (Pubitemid 351552656)
8. Steidler L, Neirynck S, Huyghebaert N, Snoeck V, Vermeire A, Goddeeris B, Cox E, Remon JP, Remaut E. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat Biotechnol 2003; 21:785-9; PMID:12808464; http://dx.doi.org/10.1038/nbt840 (Pubitemid 36791397)
9. Steidler L, Rottiers P. Therapeutic drug delivery by genetically modified Lactococcus lactis. Ann N Y Acad Sci 2006; 1072:176-86; PMID:17057198; http://dx.doi.org/10.1196/annals.1326.031 (Pubitemid 44448451)
10. Vandenbroucke K, Hans W, Van Huysse J, Neirynck S, Demetter P, Remaut E, Rottiers P, Steidler L. Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice. Gastroenterology 2004; 127:502- 13; PMID:15300583; http://dx.doi.org/10.1053/j. gastro.2004.05.020 (Pubitemid 39091899)
11. Wang Z, Gao J, Yu Q, Yang Q. Oral immunization with recombinant Lactococcus lactis expressing the hemagglutinin of the avian influenza virus induces mucosal and systemic immune responses. Future Microbiol 2012; 7:1003-10; PMID:22913358; http://dx.doi.org/10.2217/fmb.12.69
12. Wells J. Mucosal vaccination and therapy with genetically modified lactic acid bacteria. Annu Rev Food Sci Technol 2011; 2:423-45; PMID:22129390; http://dx.doi.org/10.1146/annurev-food-022510-133640
13. Bolhassani A, Zahedifard F. Therapeutic live vaccines as a potential anticancer strategy. Int J Cancer 2012; 131:1733-43; PMID:22610886; http://dx.doi. org/10.1002/ijc.27640
14. Ribelles P, Benbouziane B, Langella P, Suárez JE, Bermúdez-Humarán LG. Protection against human papillomavirus type 16-induced tumors in mice using non-genetically modified lactic acid bacteria displaying E7 antigen at its surface. Appl Microbiol Biotechnol 2013; 97:1231-9; PMID:23212671; http://dx.doi.org/10.1007/s00253-012-4575-1
15. Takiishi T, Korf H, Van Belle TL, Robert S, Grieco FA, Caluwaerts S, Galleri L, Spagnuolo I, Steidler L, Van Huynegem K, et al. Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice. J Clin Invest 2012; 122:1717-25; PMID:22484814; http://dx.doi.org/10.1172/JCI60530
16. EU Council Directive 2009/41/EC on the contained use of genetically modified micro-organisms [Internet]. Official Journal L 125, 21/05/2009 P. 0075 - 0097; Available from: http://eur-lex.europa. eu/LexUriServ/LexUriServ.do?uri= OJ:L:2009:125: 0075:01:EN:HTML - Last accessed May, 21st 2012.
17. Lee P. Biocontainment strategies for live lactic acid bacteria vaccine vectors. Bioeng Bugs 2010; 1:75- 7; PMID:21327129; http://dx.doi.org/10.4161/ bbug.1.1.10594
18. Ahmad SI, Kirk SH, Eisenstark A. Thymine metabolism and thymineless death in prokaryotes and eukaryotes. Annu Rev Microbiol 1998; 52:591-625; PMID:9891809; http://dx.doi.org/10.1146/annurev. micro.52.1.591 (Pubitemid 28481203)
19. Leenhouts K, Buist G, Bolhuis A, ten Berge A, Kiel J, Mierau I, Dabrowska M, Venema G, Kok J. A general system for generating unlabelled gene replacements in bacterial chromosomes. Mol Gen Genet 1996; 253:217-24; PMID:9003306; http://dx.doi. org/10.1007/s004380050315 (Pubitemid 26420007)
20. Maguin E, Duwat P, Hege T, Ehrlich D, Gruss A. New thermosensitive plasmid for gram-positive bacteria. J Bacteriol 1992; 174:5633-8; PMID:1324906
21. Law J, Buist G, Haandrikman A, Kok J, Venema G, Leenhouts K. A system to generate chromosomal mutations in Lactococcus lactis which allows fast analysis of targeted genes. J Bacteriol 1995; 177:7011-8; PMID:8522504
22. Dower WJ, Miller JF, Ragsdale CW. High efficiency transformation of E. coli by high voltage electroporation. Nucleic Acids Res 1988; 16:6127- 45; PMID:3041370; http://dx.doi.org/10.1093/ nar/16.13.6127
23. Geertsma ER, Poolman B. High-throughput cloning and expression in Lactococcus lactis. Protocol Exchange [Internet] 2007; Available from: http://www.nature.com/protocolexchange/protocols/287
24. Gerber SD, Solioz M. Efficient transformation of Lactococcus lactis IL1403 and generation of knockout mutants by homologous recombination. J Basic Microbiol 2007; 47:281-6; PMID:17518422; http://dx.doi.org/10.1002/jobm. 200610297 (Pubitemid 46954401)
25. Jensen PR, Hammer K. Minimal Requirements for Exponential Growth of Lactococcus lactis. Appl Environ Microbiol 1993; 59:4363-6; PMID:16349136 (Pubitemid 23361434)